BRVE
Braveheart Bio, Inc. · Healthcare · Market cap $1.9B
Insiders bought $159.0M net in the last 90 days ·0 sellers, 10 buyers· latest Form 4 filed Aug 11, 2026
Insider Buying
$159.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
10
in the rolling window
Latest filing
Aug 11, 2026
AH Bio Fund IV, L.P.
Braveheart Bio, Inc. (BRVE) has 11 SEC Form 4 filings (19 transaction rows) in the rolling window, disclosed by 10 distinct insiders. Most recent filing: Aug 11, 2026.
Inside the rolling window, 10 insiders at Braveheart Bio, Inc. reported 10 open-market purchases totaling $159.0M and no open-market sales. Insiders have net bought $159.0M over the trailing 6 months. The largest single insider purchase in this window was $64.8M by 10% Owner Forbion Growth Opportunities Fund III Cooperatief U.A. on Aug 7, 2026. The most recent open-market filing is a purchase of 1,100,000 shares by 10% Owner AH Bio Fund IV, L.P., dated Aug 7, 2026, worth $19.8M.
- Industry:Biotechnology
- CEO:Travis Murdoch
- HQ:San Francisco, CA, US
- IPO:2026-08-06
| Source | |||||||
|---|---|---|---|---|---|---|---|
AH Bio Fund IV, L.P.First filing | 10% Owner | Purchase | 1,100,000 | $19.8M | Aug 11 | -15.9% | SEC ↗ |
| Director, 10% Owner | Purchase | 1,940,000 | $34.9M | Aug 11 | -15.9% | SEC ↗ | |
Chimovits ErezFirst filing | Director, 10% Owner | Purchase | 1,940,000 | $34.9M | Aug 11 | -15.9% | SEC ↗ |
| 10% Owner | Purchase | 3,600,000 | $64.8M | Aug 7 | -29.9% | SEC ↗ | |
Anderson Michele A.First filing | Chief Development Officer | Purchase | 1,111 | $20K | Aug 7 | -29.9% | SEC ↗ |
Murdoch TravisFirst filing | CEO and President | Purchase | 83,333 | $1.5M | Aug 7 | -29.9% | SEC ↗ |
Lubner David CharlesFirst in 7 months | Director | Purchase | 55,555 | $1000K | Aug 7 | -29.9% | SEC ↗ |
Rickey James PaulFirst filing | Chief Financial Officer | Purchase | 27,777 | $500K | Aug 7 | — | SEC ↗ |
Malek David IFirst filing | Director | Purchase | 4,166 | $75K | Aug 7 | — | SEC ↗ |
Viehbacher ChristopherFirst filing | Director | Purchase | 83,333 | $1.5M | Aug 7 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does BRVE have?
Braveheart Bio, Inc. (BRVE) has 11 SEC Form 4 filings (19 transaction rows) in the rolling 365-day window, disclosed by 10 distinct insiders. Most recent filing: Aug 11, 2026.
When was the most recent SEC Form 4 filing for BRVE?
The most recent Form 4 filing for BRVE on Tracefour is dated Aug 11, 2026.
What is the net insider flow at BRVE over the last 6 months?
Over the trailing 180 days, insiders at BRVE have net bought $159.0M based on SEC Form 4 disclosures.
What was the largest insider purchase at BRVE?
The largest single insider open-market purchase at BRVE in the rolling window was $64.8M by 10% Owner Forbion Growth Opportunities Fund III Cooperatief U.A. on 2026-08-07.
What is the total insider buy and sell value at BRVE in the current window?
Inside the rolling window, insiders at BRVE bought $159.0M and sold $0 based on SEC Form 4 filings.
Can I get alerts for BRVE insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Braveheart Bio, Inc. (BRVE). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Braveheart Bio, Inc. is in the Healthcare sector.